819076-91-0

Basic information

• Product Name: methyl 2-chlorobenzo[d]oxazole-6-carboxylate
• Synonyms: methyl 2-chlorobenzo[d]oxazole-6-carboxylate;METHYL 2-CHLORO-1,3-BENZOXAZOLE-6-CARBOXYLATE
• CAS NO: 819076-91-0
• Molecular Formula: C₉H₆ClNO₃
• Molecular Weight: 211.60184
• Mol File: 819076-91-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 2-chlorobenzo[d]oxazole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-chlorobenzo[d]oxazole-6-carboxylate(819076-91-0)
• EPA Substance Registry System: methyl 2-chlorobenzo[d]oxazole-6-carboxylate(819076-91-0)

Safety Data

• Hazardous Substances Data: 819076-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chlorobenzo[d]oxazole-6-carboxylate is used as a building block for the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable intermediate in the development of drugs for a wide range of medical conditions.
Used in Drug Development:
Methyl 2-chlorobenzo[d]oxazole-6-carboxylate is used as a key intermediate in the development of new drugs. Its potential applications in treating various medical conditions make it an important component in pharmaceutical research and development.

Upstream product

• 63435-16-5 3-hydroxy-4-aminobenzoic acid methyl ester 
• 72752-81-9 methyl 2-mercapto-1,3-benzoxazole-6-carboxylate 

Downstream Products

• 1224465-36-4 methyl 2-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)benzo[d]oxazole-6-carboxylate 

Relevant articles and documents

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS

The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hype

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition

We report new SSTR5 antagonists with enhanced potency, subtype selectivity, and minimal off-target activities as compared to previously reported compounds. Starting from the reported SSTR5 antagonist 1, we systematically surveyed changes in the central core and head piece while maintaining the diphenyl tail group constant. From this study the azaspirodecanone 10 emerged as a new highly potent and selective SSTR5 antagonist. Compound 10 lowered glucose excursion by 94% in an oral glucose tolerance test (OGTT) in mice following a 3 mg/kg oral dose. The compound increased both total and active circulating incretin hormone GLP-1 levels in mice at a dose of 10 mg/kg. A synergistic effect was also demonstrated when compound 10 was coadministered with a DPP-4 inhibitor, substantially increasing circulating active GLP-1[7-36] amide and insulin in response to a glucose challenge.

Analgesic Compounds, Compositions, and Uses Thereof

The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.

SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES

Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5

BENZOOXAZOLE, OXAZOLOPYRIDINE, BENZOTHIAZOLE AND THIAZOLOPYRIDINE DERIVATIVES

This invention is concerned with compounds of the formula (I) wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical

Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: Heterocyclic P3

A series of Nα-2-benzoxazolyl-α-amino acid-(arylaminoethyl)amides were identified as potent, selective, and noncovalent inhibitors of cathepsin S. Structure-activity relationships including strategies for modulating the selectivities among cathepsins S, K, and L, and in vivo pharmacokinetics are discussed. A X-ray structure of compound 3 bound to the active site of cathepsin S is also reported.